Literature DB >> 14607280

Regulation of the insulin receptor by protein kinase C isoenzymes: preferential interaction with beta isoenzymes and interaction with the catalytic domain of betaII.

Tahir S Pillay1, Sen Xiao, Lisa Keranen, Jerrold M Olefsky.   

Abstract

We analysed the effects of high glucose in rat1 cells overexpressing insulin receptor. High (25 mM) glucose inhibited insulin-stimulated tyrosine kinase activity completely at insulin concentrations of 1 and 5 ng/ml. Decapeptides modelled on insulin receptor sequences surrounding serines 1035 and 1270 were found to inhibit protein kinase C activity in vitro and after microinjection into cells blocked the inhibition of mitogenesis induced by glucose. Purification of receptor from 3T3L1 adipocytes revealed that only the isoenzymes beta1, betaII and delta were detected. The site of the interaction was mapped to the catalytic domain of betaII. These results demonstrate that the inhibition of insulin receptor tyrosine kinase activity can be ameliorated using insulin receptor peptide sequences and there is constitutive and differential interaction of individual PKC isoenzymes with the insulin receptor, and in the case of betaII, this interaction maps to the catalytic domain rather than the regulatory domain.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14607280     DOI: 10.1016/s0898-6568(03)00090-1

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  8 in total

Review 1.  Specific protein kinase C isoforms as transducers and modulators of insulin signaling.

Authors:  Sanford R Sampson; Denise R Cooper
Journal:  Mol Genet Metab       Date:  2006-06-23       Impact factor: 4.797

2.  Phosphorylation of the insulin receptor by AMP-activated protein kinase (AMPK) promotes ligand-independent activation of the insulin signalling pathway in rodent muscle.

Authors:  I Chopra; H F Li; H Wang; K A Webster
Journal:  Diabetologia       Date:  2011-12-30       Impact factor: 10.122

3.  Hyperglycemia potentiates H(2)O(2) production in adipocytes and enhances insulin signal transduction: potential role for oxidative inhibition of thiol-sensitive protein-tyrosine phosphatases.

Authors:  Xiangdong Wu; Li Zhu; Assaf Zilbering; Kalyankar Mahadev; Hiroyuki Motoshima; Junli Yao; Barry J Goldstein
Journal:  Antioxid Redox Signal       Date:  2005 May-Jun       Impact factor: 8.401

4.  Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors.

Authors:  Adam Denley; Julie M Carroll; Gemma V Brierley; Leah Cosgrove; John Wallace; Briony Forbes; Charles T Roberts
Journal:  Mol Cell Biol       Date:  2007-02-26       Impact factor: 4.272

5.  Inhibition of protein kinase Cepsilon prevents hepatic insulin resistance in nonalcoholic fatty liver disease.

Authors:  Varman T Samuel; Zhen-Xiang Liu; Amy Wang; Sara A Beddow; John G Geisler; Mario Kahn; Xian-man Zhang; Brett P Monia; Sanjay Bhanot; Gerald I Shulman
Journal:  J Clin Invest       Date:  2007-02-22       Impact factor: 14.808

6.  Endoplasmic reticulum stress promotes LIPIN2-dependent hepatic insulin resistance.

Authors:  Dongryeol Ryu; Woo-Young Seo; Young-Sil Yoon; Yo-Na Kim; Su Sung Kim; Hye-Jin Kim; Tae-Sik Park; Cheol Soo Choi; Seung-Hoi Koo
Journal:  Diabetes       Date:  2011-02-25       Impact factor: 9.461

7.  Angiotensin II Inhibits Insulin Receptor Signaling in Adipose Cells.

Authors:  Citlaly Gutierrez-Rodelo; Araceli Arellano-Plancarte; Judith Hernandez-Aranda; Huguet V Landa-Galvan; G Karina Parra-Mercado; Nicole J Moreno-Licona; Karla D Hernandez-Gonzalez; Kevin J Catt; Rafael Villalobos-Molina; J Alberto Olivares-Reyes
Journal:  Int J Mol Sci       Date:  2022-05-27       Impact factor: 6.208

8.  Functional involvement of protein kinase C-betaII and its substrate, myristoylated alanine-rich C-kinase substrate (MARCKS), in insulin-stimulated glucose transport in L6 rat skeletal muscle cells.

Authors:  D S Chappell; N A Patel; K Jiang; P Li; J E Watson; D M Byers; D R Cooper
Journal:  Diabetologia       Date:  2009-02-28       Impact factor: 10.122

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.